• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

鞘内利妥昔单抗治疗移植后 EBV 相关淋巴增殖性疾病所致中枢神经系统受累的疗效

Successful Treatment of Central Nervous System Involvement in Posttransplant EBV-related Lymphoproliferative Disease With Intrathecal Rituximab Therapy.

机构信息

Departments of Pediatric Hematology.

Otolaryngology-Head and Neck Surgery.

出版信息

J Pediatr Hematol Oncol. 2023 Jul 1;45(5):e628-e630. doi: 10.1097/MPH.0000000000002592. Epub 2022 Nov 15.

DOI:10.1097/MPH.0000000000002592
PMID:36730621
Abstract

The posttransplant lymphoproliferative disease is a severe cause of morbidity and mortality following allogeneic hematopoietic stem cell transplantation. Central Nervous System involvement in EBV-related PTLD is rare, and there is no standard treatment recommendation. We present our patient and discuss other previously reported cases of EBV-associated PTLD with CNS involvement.

摘要

移植后淋巴组织增生性疾病是异基因造血干细胞移植后发病率和死亡率的严重原因。 EBV 相关的 PTLD 累及中枢神经系统的情况较为罕见,也没有标准的治疗推荐。我们介绍了我们的患者,并讨论了其他先前报道的 EBV 相关的累及中枢神经系统的 PTLD 病例。

相似文献

1
Successful Treatment of Central Nervous System Involvement in Posttransplant EBV-related Lymphoproliferative Disease With Intrathecal Rituximab Therapy.鞘内利妥昔单抗治疗移植后 EBV 相关淋巴增殖性疾病所致中枢神经系统受累的疗效
J Pediatr Hematol Oncol. 2023 Jul 1;45(5):e628-e630. doi: 10.1097/MPH.0000000000002592. Epub 2022 Nov 15.
2
Intrathecal therapy with rituximab in central nervous system involvement of post-transplant lymphoproliferative disorder.鞘内注射利妥昔单抗治疗移植后淋巴组织增生性疾病中枢神经系统累及。
Leuk Lymphoma. 2013 Mar;54(3):503-6. doi: 10.3109/10428194.2012.718342. Epub 2012 Aug 31.
3
Post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation: a case report, meta-analysis, and systematic review.异基因造血干细胞移植后移植后淋巴组织增生性疾病:病例报告、荟萃分析和系统评价。
Diagn Pathol. 2024 Sep 7;19(1):122. doi: 10.1186/s13000-024-01544-8.
4
Ofatumumab for Post-Transplant Lymphoproliferative Disorder.奥法木单抗用于移植后淋巴细胞增生性疾病
Hematol Oncol Stem Cell Ther. 2022 Mar 1;15(1):68-73. doi: 10.1016/j.hemonc.2020.04.004.
5
Epstein-Barr virus related post-transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植中与爱泼斯坦-巴尔病毒相关的移植后淋巴细胞增殖性疾病预防策略
Rev Med Virol. 2020 Jul;30(4):e2108. doi: 10.1002/rmv.2108. Epub 2020 Apr 17.
6
Epstein-Barr virus-associated post-transplant lymphoproliferative disease with central nervous system involvement after unrelated allogeneic hematopoietic stem cell transplantation.非血缘异基因造血干细胞移植后发生的伴有中枢神经系统受累的爱泼斯坦-巴尔病毒相关移植后淋巴细胞增殖性疾病
Leuk Lymphoma. 2006 Jan;47(1):167-9. doi: 10.1080/10428190500254208.
7
Pre-Hematopoietic Stem Cell Transplantation Rituximab for Epstein-Barr Virus and Post-Lymphoproliferative Disorder Prophylaxis in Alemtuzumab Recipients.阿仑单抗治疗患者的造血干细胞移植前利妥昔单抗预防 EBV 和后淋巴组织增生性疾病
Transplant Cell Ther. 2023 Feb;29(2):132.e1-132.e5. doi: 10.1016/j.jtct.2022.10.023. Epub 2022 Nov 9.
8
T-cell posttransplant lymphoproliferative disorders after allogeneic hematopoietic cell transplantation.异基因造血细胞移植后 T 细胞移植后淋巴组织增生性疾病。
Int J Hematol. 2020 Aug;112(2):193-199. doi: 10.1007/s12185-020-02890-1. Epub 2020 May 29.
9
Central Nervous System Involvement in Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorders after Allogeneic Hematopoietic Stem Cell Transplantation.异基因造血干细胞移植后 EBV 相关移植后淋巴增殖性疾病的中枢神经系统受累。
Transplant Cell Ther. 2021 Mar;27(3):261.e1-261.e7. doi: 10.1016/j.jtct.2020.12.019. Epub 2020 Dec 22.
10
Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.儿童和成人造血干细胞移植后 EBV 相关淋巴组织增生性疾病对利妥昔单抗治疗的反应及危险因素分析:来自欧洲血液和骨髓移植学会传染病工作组的研究。
Clin Infect Dis. 2013 Sep;57(6):794-802. doi: 10.1093/cid/cit391. Epub 2013 Jun 13.